Aardvark Q1 net loss widens to $21.6 million; R&D expenses rise to $16.6 million

Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc.

AARD

0.00
  • Aardvark Therapeutics posted a Q1 net loss of USD 21.6 million, widening from USD 9.3 million a year earlier; R&D expense climbed to USD 16.6 million from USD 7.8 million.
  • G&A expense rose to USD 5.9 million from USD 2.7 million.
  • Cash, cash equivalents and short-term investments fell to USD 91.2 million as of March 31 from USD 110 million at year-end; runway projected into mid-2027.
  • Enrollment and dosing remain voluntarily paused in Phase 3 HERO and OLE trials of lead candidate ARD-101 following unexpected reversible cardiac observations in a separate healthy-volunteer study; further guidance expected in Q2 2026.
  • Development of ARD-201 was also voluntarily paused in March; CEO Tien Lee said the company is working with FDA to evaluate data and establish a path forward for the ARD-101 program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070800PRIMZONEFULLFEED9715300) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.